AU2001271700A1 - Controlled release arginine formulations - Google Patents

Controlled release arginine formulations

Info

Publication number
AU2001271700A1
AU2001271700A1 AU2001271700A AU7170001A AU2001271700A1 AU 2001271700 A1 AU2001271700 A1 AU 2001271700A1 AU 2001271700 A AU2001271700 A AU 2001271700A AU 7170001 A AU7170001 A AU 7170001A AU 2001271700 A1 AU2001271700 A1 AU 2001271700A1
Authority
AU
Australia
Prior art keywords
controlled release
arginine formulations
arginine
release arginine
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271700A
Inventor
Wayne H. Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitrosystems Inc
Original Assignee
Nitrosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitrosystems Inc filed Critical Nitrosystems Inc
Publication of AU2001271700A1 publication Critical patent/AU2001271700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. Figure 1A shows a schematic representation of proposed L-arginine dependent and independent pahtways.
AU2001271700A 2000-06-28 2001-06-28 Controlled release arginine formulations Abandoned AU2001271700A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60559900A 2000-06-28 2000-06-28
US09605599 2000-06-28
PCT/US2001/020887 WO2002000212A1 (en) 2000-06-28 2001-06-28 Controlled release arginine formulations

Publications (1)

Publication Number Publication Date
AU2001271700A1 true AU2001271700A1 (en) 2002-01-08

Family

ID=24424380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271700A Abandoned AU2001271700A1 (en) 2000-06-28 2001-06-28 Controlled release arginine formulations

Country Status (8)

Country Link
EP (1) EP1377284B1 (en)
JP (1) JP2004513877A (en)
AT (1) ATE417609T1 (en)
AU (1) AU2001271700A1 (en)
CA (1) CA2413816A1 (en)
DE (1) DE60137082D1 (en)
MX (1) MXPA03000194A (en)
WO (1) WO2002000212A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175210A4 (en) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Increasing cerebral bioavailability of drugs
EP1492508A4 (en) * 2002-03-04 2009-05-06 Teva Pharma Controlled release dosage forms
AU2004279298B2 (en) * 2003-09-29 2009-01-29 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
JP2010270111A (en) * 2009-04-21 2010-12-02 Taisho Pharmaceutical Co Ltd Arginine-containing tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2827287B2 (en) * 1988-07-05 1998-11-25 武田薬品工業株式会社 Sustained release microcapsules containing water-soluble drugs
ES2042292T3 (en) * 1989-03-17 1993-12-01 Pitman-Moore, Inc. DEVICE FOR THE ADMINISTRATION OF MACROMOLECULAR PROTEINS BY CONTROLLED RELEASE.
US5824331A (en) * 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US20020068365A1 (en) * 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
EP1175210A4 (en) * 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Increasing cerebral bioavailability of drugs
AU1800801A (en) * 1999-11-17 2001-05-30 Eric H. Kuhrts Exercise and muscle enhancement formulations

Also Published As

Publication number Publication date
EP1377284A1 (en) 2004-01-07
MXPA03000194A (en) 2004-09-13
EP1377284B1 (en) 2008-12-17
JP2004513877A (en) 2004-05-13
ATE417609T1 (en) 2009-01-15
EP1377284A4 (en) 2006-04-12
DE60137082D1 (en) 2009-01-29
WO2002000212A1 (en) 2002-01-03
CA2413816A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2603400A (en) Formulations for treating disease and methods of using same
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2003274387A1 (en) Power amplifying system with supply and bias enhancements
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001294876A1 (en) Direct growth of nanotubes, and their use in nanotweezers
AU2002230642A1 (en) Proton generating catheters and methods for their use
AU2001267475A1 (en) Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof
AU2001230902A1 (en) Slow-release insect-repellent composition and uses
DK0695172T3 (en) Fast-release solid preparation, its preparation and its use
AU2002316677A1 (en) Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa
AU2001279703A1 (en) Garment
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2002036145A3 (en) Kahalalide f formulation
AU2002322468A1 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU4843500A (en) Destructible surfactants and uses thereof
AU2001271700A1 (en) Controlled release arginine formulations
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
AU2001230355A1 (en) Benzoxazole derivatives and their use as pesticides
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2002239369A1 (en) Eukaryotic expression libraries based on double lox recombination and methods of use
IL154073A0 (en) Pyruvate: nadp+ oxidoreductase and uses thereof
AU2001237592A1 (en) Enzymes and uses relating thereto
AU2001291962A1 (en) Angiogenic agents and their uses
AU1784900A (en) Compositions in anhydrous medium comprising active principles releasing a gas incontact with water, and uses thereof